MedTrace Logo

A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.

NCT03286205 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-06-05

No results posted yet for this study

Summary

The purpose of this study is to establish which dosing schedule of INfed (Iron dextrose) is superior for the treatment of iron deficient anemia.

Conditions

  • Anemia, Iron Deficiency

Interventions

DRUG

IV iron

IV iron infusion based on weekly or every 3 week dosage.

Sponsors & Collaborators

  • Sutter Gould Medical Foundation

    lead OTHER

Principal Investigators

  • David Adkins, MD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-14
Primary Completion
2018-08-31
Completion
2018-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03286205 on ClinicalTrials.gov